RadMD

??Still time to Register! Join doctors Rick Patt, MD, Kohkan Shamsi, and Juan E. Gutierrez M.D. on March 20th for an insightful live webinar, "The Full Picture: RECIST PLUS," where we’ll dive deep into the evolution of oncology imaging, the limitations of RECIST 1.1, and how additional measurements can enhance early-phase decision making and late-phase efficacy confirmation in clinical trials. ?? Don't miss this opportunity to engage with our medical experts! ?? Register now: https://lnkd.in/ek88Rgwz #RECIST #OncologyResearch #ClinicalTrials #MedicalImaging #Webinar

Our team is excited to attend IO360 in just a few weeks and we look forward to connecting with you there! Mark your calendars! Stop by our booth to discuss: - Innovative imaging solutions for immunotherapies - RECIST Plus & how additional imaging insights (beyond RECIST 1.1) are crucial for decision-making - Current and future uses of AI in imaging for clinical trials - Opportunities for collaboration and partnership

Today, on International Women’s Day, we celebrate the many talented women driving advancements in medical imaging and clinical research. From radiologists, imaging scientists, data analysts, clinical trial experts and all women working together to transform medicine and patient outcomes. Thank you for your dedication, expertise, and leadership! ?? #InternationalWomensDay #WomenInScience #MedicalImaging #ClinicalResearch

The landscape of oncology clinical trials has evolved significantly since RECIST 1.1 was introduced, especially with the advent of immunotherapies, cell therapies, and other novel therapies. While RECIST 1.1 criteria remains a cornerstone for assessing tumor response, it does not always capture the full picture. Join us for an interactive webinar where we’ll discuss: ?? How imaging has advanced and evolved to become more sophisticated since RECIST 1.1 to address new therapy challenges ?? Why additional imaging insights are crucial for decision-making in early-phase and treatment monitoring in later phase trials ?? RECIST Plus – a set of enhanced tools that augment traditional RECIST 1.1 measurements Discover how these advancements can provide a deeper understanding of drug mechanism of action, treatment response and improve trial outcomes. ??March 20, 2025 ?? Register now! https://lnkd.in/ekPKtF4c #OncologyTrials #RECIST #Immunotherapy #ClinicalResearch #MedicalImaging

Ramadan Mubarak from RadMD! Wishing our clients and partners a blessed and peaceful Ramadan.

February is National Cancer Prevention month! It is estimated that there were 20 million new cases of cancer worldwide in 2024 and it remains the leading cause of death. At RadMD, we are dedicate to advancing the fight against cancer. Our commitment to innovation, a collaborative approach and expert insights ensure that clinical trials are supported by precise and reliable data, paving the way for innovative treatments and early detection. Prevention is paramount while treatments are developed; here are a few ways you can contribute to cancer prevention: - Regular Screenings: Early detection saves lives. Be sure to stay on top of recommended screenings - Healthy Lifestyle Choices; Maintain a balanced diet; exercise regularly and avoid processed foods - Stay Informed; Knowledge is power. Keep yourself updated on latest research and guidelines related to cancer preventions - Spread Awareness: Use your voice to raise awareness about cancer prevention and importance of early detection. Together we can make a difference. #cancerprevention #imagingCRO #clinicaltrials

RadMD is currently looking for experienced medical professionals to join our Reader Service team as Independent Reviewers in clinical trials. Your expertise could help shape the future of medicine and improve patient outcomes. Candidates must be US Board certified; 5+ years experience in Thoracic Imaging, Mammography, Dermatology and Neuroradiology. ?? Why Join? Contribute to medical research and collaborate with top experts ?? Commitment: Contractor ?? Location: Remote If you or someone you know is interested, let’s connect! Please contact Pam Santana [email protected] now for this exciting opportunity at RadMD.

It's Gallbladder and Bile Cancer Awareness Month. These cancers are rare (12,530 cases in 2024) but often diagnosed late due to vague symptoms, resulting in lower survival rates. For example, the 5-year survival rate for gallbladder cancer ranges from 4% at an advanced stage to 68% when localized. In 2024, there were 4,530 deaths from these cancers. In November 2024, the FDA granted accelerated approval for a new drug to treat advanced bile duct cancer and other biliary tract cancers with high HER2 levels that don't respond to chemotherapy. Our clinical trial imaging expertise continues to support treatment and survival in these cancers, and we're proud to see the industry advancing with new treatments. Connect with us at [email protected] to learn more! #CancerAwareness #GallbladderCancer #BileDuctCancer #CancerResearch #clinicaltrials #imaging

We are pleased to present RECIST Plus, an enhanced analysis option that augments traditional RECIST 1.1 linear diameter measurements with comprehensive volumetric and radiological parameters at no additional cost to our partners! Key Analytical Features: ? Comprehensive volumetric tumor quantification ? Density measurement analysis across lesion profiles ? Advanced radiomics feature extraction (60+ parameters) ? Detailed morphological characterization of response and progression patterns ? Quantitative tumor vascularity assessment RECIST Plus enables deeper insights into therapeutic efficacy through multi-parametric analysis, facilitating more nuanced understanding of treatment response. For detailed technical specifications and implementation protocols, please contact our team for a comprehensive consultation.

Only one day left to meet our very own Judy Currier and Jonna T. at OCT West Coast 2025! ??Meet the RadMD team and discover how we are raising the bar for clinical trials. Our expert services and innovative solutions provide you additional information beyond standard RECIST 1.1 measurements. Drop by booth #26 to learn how we can enhance your trial's success. ?? Come say hello! #OCTWestCoast2025 #ImagingCoreLab #ClinicalTrials #ClinicalResearch #MedicalImaging